Keyphrases
Hyperphosphatemia
100%
Sucroferric Oxyhydroxide
100%
Phosphate Binder
85%
Serum Phosphorus
57%
Dependent Patients
42%
Dialysis-dependent
42%
Pill Burden
42%
Phosphorus Control
28%
Clinical Trials
14%
Monotherapy
14%
Europe
14%
Randomized Controlled Trial
14%
Chronic Kidney Disease
14%
Common Complications
14%
Clinical Practice
14%
Nave
14%
Hemodialysis
14%
Treatment Setting
14%
Tolerability
14%
Medication Use
14%
Treatment Adherence
14%
Clinical Trial Data
14%
Iron Absorption
14%
Peritoneal Dialysis Patients
14%
Real-world Clinical Practice
14%
Patient Needs
14%
Real-world Use
14%
Patient Monitor
14%
Sevelamer Carbonate
14%
Real-world Observational Study
14%
Iron-based Phosphate Binders
14%
Medicine and Dentistry
Hyperphosphatemia
100%
Sucroferric Oxyhydroxide
100%
Phosphate Binder
100%
Real-World Evidence
100%
Observational Study
42%
Clinical Trial
28%
Monotherapy
14%
Randomized Controlled Trial
14%
Patient Compliance
14%
Hemodialysis
14%
Chronic Kidney Disease
14%
Peritoneal Dialysis
14%
Iron Absorption
14%
Iron
14%
Sevelamer Carbonate
14%
Oral
14%
Real-World Data
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hyperphosphatemia
100%
Sucroferric Oxyhydroxide
100%
Phosphate Binding Agent
100%
Observational Study
42%
Clinical Trial
28%
Iron
28%
Monotherapy
14%
Randomized Controlled Trial
14%
Chronic Kidney Failure
14%
Tolerability
14%
Hemodialysis
14%
Sevelamer Carbonate
14%